冠状动脉脆弱斑块的管理:专注于预防性皮肤穿冠状动脉干预
Stefano Rigattieri1, Marco Redivo1, Matteo Casenghi1
1Cardiology Division, Sant'Andrea University Hospital, 00189 Rome, Italy.
Reviews in cardiovascular medicine
|May 12, 2025
概括
检测和治疗脆弱的冠状动脉斑块 (VPs) 对于预防心脏病发作至关重要. 先进的成像和干预措施为管理这些高风险病变在引起血栓形成之前提供了新的策略.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 医疗成像医学成像
背景情况:
- 脆弱斑块 (VPs) 是血管学上轻度至中度的冠状动脉病变,具有高风险特征,如大脂质核和细纤维状盖.
- 在大约三分之二的急性冠状动脉综合征病例中,这些斑块是冠状动脉血栓形成的主要基质.
- 早期发现和管理VP对于预防心血管事件至关重要.
研究的目的:
- 提供关于脆弱斑块的定义,检测和预后价值的最新审查.
- 讨论目前和新兴的药理和干预管理策略对VP.
- 探索预防性皮肤冠状动脉干预的概念,用于高风险,不显著的病变.
主要方法:
- 对VP检测的非侵入性和侵入性成像技术的审查 (例如,CCT,MRI,IVUS,OCT,NIRS).
- 病理学研究的分析,定义VP的特征.
- 从观察性研究中对VP与心血管事件相关的证据的评估.
- 对药物 (降脂) 和干预 (支架,支架,DCBs) 疗法的评估.
主要成果:
- 易受伤害的斑块可以使用各种先进的成像方式来识别.
- 目前正在研究药理和干预策略,以回归或稳定VP.
- 预防性穿皮冠状动脉干预针对具有高风险斑块特征的非显著病变.
结论:
- 易受伤害的斑块检测和表征正在迅速推进.
- 药理学和干预方法的结合对管理与VP相关的心血管风险具有前景.
- 需要进一步的研究来优化对高风险冠状动脉斑块的预防策略.
更多相关视频
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
405
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
405
01:17Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
402
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
402
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
103
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
103